Smoking Cessation — An Innovation to Increase Smoking Quit Rate
Citation(s)
Abdulateef DS, Ali AJ, Abdulateef DS, Mohesh MI Smoking Knowledge, Attitude, and Practices Among Health Care Professionals from Sulaymaniyah City/Iraq. Tob Use Insights. 2016 Mar 3;9:1-6. doi: 10.4137/TUI.S38171. eCollection 2016.
Beck RS, Daughtridge R, Sloane PD Physician-patient communication in the primary care office: a systematic review. J Am Board Fam Pract. 2002 Jan-Feb;15(1):25-38. Review.
Buchhalter AR, Fant RV, Henningfield JE Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs. 2008;68(8):1067-88. Review.
Jepson RG, Harris FM, Platt S, Tannahill C The effectiveness of interventions to change six health behaviours: a review of reviews. BMC Public Health. 2010 Sep 8;10:538. doi: 10.1186/1471-2458-10-538. Review.
Kenny PJ, Markou A Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav. 2001 Dec;70(4):531-49. Review.
Lu AS, Kharrazi H A State-of-the-Art Systematic Content Analysis of Games for Health. Games Health J. 2018 Feb;7(1):1-15. doi: 10.1089/g4h.2017.0095. Epub 2018 Jan 2. Review.
Tan JW, Zary N Diagnostic Markers of User Experience, Play, and Learning for Digital Serious Games: A Conceptual Framework Study. JMIR Serious Games. 2019 Jul 16;7(3):e14620. doi: 10.2196/14620.
Xi ZX, Spiller K, Gardner EL Mechanism-based medication development for the treatment of nicotine dependence. Acta Pharmacol Sin. 2009 Jun;30(6):723-39. doi: 10.1038/aps.2009.46. Epub 2009 May 11. Review.
An Innovation Involving Self-Surveillance and Serious Gaming to Increase Smoking Quit Rate: Protocol for a Randomized Controlled Trial
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
